Tuvirumab

Tuvirumab is a human monoclonal antibody for the treatment of patients with chronic hepatitis B. It has undergone Phase I clinical trials in 2001.^[1]^[2]

References

↑ Heijtink, RA; Van Nunen, AB; Van Bergen, P; Ostberg, L; Osterhaus, AD; De Man, RA (2001). "Administration of a human monoclonal antibody (TUVIRUMAB) to chronic hepatitis B patients pre-treated with lamivudine: monitoring of serum TUVIRUMAB in immune complexes". Journal of medical virology. 64 (4): 427–34. PMID 11468726. doi:10.1002/jmv.1068.
↑ Van Nunen, AB; Baumann, M; Manns, MP; Reichen, J; Spengler, U; Marschner, JP; De Man, RA; International Study, Group (2001). "Efficacy and safety of an intravenous monoclonal anti-HBs in chronic hepatitis B patients". Liver. 21 (3): 207–12. PMID 11422784. doi:10.1034/j.1600-0676.2001.021003207.x.

Fungal ("-fung-")

Human ("-fungu-")	Efungumab^†

Viral ("-v(i)[r]-")

Human ("-viru-")	Diridavumab^§ Exbivirumab^§ Foravirumab^§ Libivirumab^§ Rafivirumab^§ Regavirumab^§ Sevirumab^† Tuvirumab^§
Humanized ("-vizu-")	Felvizumab^§ Motavizumab^† Palivizumab Suvizumab^§

Bacterial ("-ba(c)-")

Human ("-bacu-")	Nebacumab Panobacumab^§ Raxibacumab
Mouse ("-baco-")	Edobacomab^§
Chimeric ("-baxi-")	Pagibaximab^†
Humanized ("-bazu-")	Tefibazumab^†

Toxin ("-tox(a)-")

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.